Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

Overview of attention for article published in Journal of Hematology & Oncology, April 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

news: 2 news outlets
twitter: 7 X users

patent: 3 patents

Citations

dimensions_citation: 211 Dimensions

Readers on

mendeley: 160 Mendeley

Summary News X Patents Dimensions citations

So far, Altmetric has seen 8 X posts from 7 X users, with an upper bound of 16,507 followers.

@DrPaulyDeSantis @BloodJournal prob move to CD19+22 bi specific CAR upfront..https://t.co/BA98bfiRgP

27 May 2021

Reply Repost Favourite

RT @RenoHemonc: @RahulBanerjeeMD @BloodJournal @drkomanduri @StanfordBMT_CT @SurbhiSidanaMD @LoriMuffly @AndrewRezvani How abt bispecific…

09 May 2021

Reply Repost Favourite

@RahulBanerjeeMD @BloodJournal @drkomanduri @StanfordBMT_CT @SurbhiSidanaMD @LoriMuffly @AndrewRezvani How abt bispecific CAR 19/22 upfront? https://t.co/BA98bfAsFp

04 May 2021

Reply Repost Favourite

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. https://t.co/NZxR7QJane

26 Jan 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.